Cara Therapeutics | CARA - El Costo De Ventas





El Costo De Ventas Cambio Fecha
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Assertio Holdings USD 8.89M 2.29M 2024-06
Cara Therapeutics USD 0 0 2025-03
Cassava Sciences USD 3.96M 1.16M 2025-09
Chugai Pharma JPY 87.56B 12.68B 2025-12
Cipla INR 29.1B 1.16B 2025-12
Clal Biotechnology ILS 16.49M 2.64M 2022-06
Compugen USD 3.54M 1.89M 2025-12
CSL USD 3.87B 2.08B 2025-12
Grifols EUR 1.51B 184.45M 2025-12
Halozyme Therapeutics USD 102.15M 29.14M 2025-12
J&J USD 7.97B 689M 2025-12
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Pacira USD 54.62M 6.02M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
RedHill Biopharma USD 702K 0 2024-06
Supernus Pharmaceuticals USD 47.53M 4.24M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12